Angelini Pharma, an international pharmaceutical company, agreed to acquire Arvelle Therapeutics, a Swiss-based biopharmaceutical company focused on bringing innovative treatments to patients suffering from CNS disorders, for $960m. "At Angelini Pharma, we are thrilled to sign this promising agreement and are enthusiastic about the commitment and work that our colleagues at Arvelle have put into the business during the last years. We share the same patient-centric culture and agility attitude. This transaction will propel us into a leading European player, well positioned to address the needs of patients with different Central Nervous System disorders through an innovative portfolio, distinctive medical capabilities and extensive commercial presence, also via the opening of direct affiliates in France, UK, Nordics and Switzerland by 2022," Pierluigi Antonelli, Angelini Pharma CEO.